Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Rheumatoid Arthritis

Free Subscription Articles published in Z Rheumatol Retrieve available abstracts of 55 articles: HTML format

Single Articles

March 2023
1. FIEHN C, Leipe J, Weseloh C, Bergner R, et al
   [Assessment of interactions and dosage recommendations of synthetic DMARDs-Evidence-based and consensus-based recommendations based on a systematic literature search].
   Z Rheumatol. 2023;82:151-162.
   PubMed     Abstract available
   
   
   
2. VORDENBAUMEN S, Feist E
   [Adult-onset Still's disease : Diagnosis and treatment according to the new S2e guidelines of the German Society of Rheumatology (DGRh)].
   Z Rheumatol. 2023;82:134-142.
   PubMed     Abstract available
   
   
   
3. RATH E, Bonelli M, Duftner C, Gruber J, et al
   [National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMA
   Z Rheumatol. 2023;82:163-174.
   PubMed     Abstract available
   
   
   
4. BARALIAKOS X, Alshakaki F, Buhring B, Andreica I, et al
   [How many patients with inflammatory rheumatic diseases have the technical prerequisites for video consultations and are also willing to use this to carry out visits by medical specialist visits?].
   Z Rheumatol. 2023;82:102-107.
   PubMed     Abstract available
   
   
   February 2023
5. DE GROOT K, Schreiber JG
   [This is how I treat rheumatoid arthritis in dialysis patients].
   Z Rheumatol. 2023 Feb 28. doi: 10.1007/s00393-023-01334.
   PubMed    
   
   
   
6. FIEHN C, Zinke S, Haas JS, Meise D, et al
   Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
   Z Rheumatol. 2023 Feb 9. doi: 10.1007/s00393-023-01323.
   PubMed     Abstract available
   
   
   
7. VORDENBAUMEN S, Feist E, Rech J, Fleck M, et al
   Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline.
   Z Rheumatol. 2023;82.
   PubMed    
   
   
   January 2023
8. HO LEE Y, Gyu Song G
   Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
   Z Rheumatol. 2023 Jan 6. doi: 10.1007/s00393-022-01315.
   PubMed     Abstract available
   
   
   
9. NIEDERMANN K, Rausch AK, Braun J, Becker H, et al
   [Lay version of the 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis : Translation into German and linguistic validation in German-speaking countries with people affected].
   Z Rheumatol. 2023;82.
   PubMed     Abstract available
   
   
   
10. SIEIRO SANTOS C, Moriano Morales C, Alvarez Castro C, Diez Alvarez E, et al
    Polyautoimmunity in systemic lupus erythematosus: secondary Sjogren syndrome.
    Z Rheumatol. 2023;82.
    PubMed     Abstract available
    
    
    December 2022
11. VORDENBAUMEN S, Feist E, Rech J, Fleck M, et al
    [DGRh S2e guidelines : Diagnostic and treatment of adult-onset Still's disease (AOSD)].
    Z Rheumatol. 2022;81.
    PubMed    
    
    
    
12. VORDENBAUMEN S, Feist E, Rech J, Fleck M, et al
    [Guideline report on the DGRh S2e guidelines on diagnostics and treatment of adult-onset Still's disease (AOSD)].
    Z Rheumatol. 2022;81.
    PubMed    
    
    
    November 2022
13. LEE YH, Song GG
    Relative effectiveness and safety of interleukin-6 and Janus kinase inhibitors versus adalimumab in patients with rheumatoid arthritis: a network meta-analysis.
    Z Rheumatol. 2022 Nov 24. doi: 10.1007/s00393-022-01290.
    PubMed     Abstract available
    
    
    
14. BRUYN GA, Wong P
    The Genesis of Sjogren.
    Z Rheumatol. 2022;81:787-791.
    PubMed     Abstract available
    
    
    
15. RUBBERT-ROTH A
    [ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?]
    Z Rheumatol. 2022;81:780-781.
    PubMed    
    
    
    October 2022
16. MARKER-HERMANN E
    [Renal manifestations in rheumatoid arthritis and spondylarthritis].
    Z Rheumatol. 2022 Oct 20. pii: 10.1007/s00393-022-01279.
    PubMed     Abstract available
    
    
    September 2022
17. TRIANTAFYLLIAS K, Sauer C, Schwarting A
    [Therapeutic effects of complex multimodal rheumatologic treatment in the Rheumatology Center, Rhineland-Palatinate].
    Z Rheumatol. 2022;81:596-604.
    PubMed     Abstract available
    
    
    August 2022
18. ALBRECHT K, Leipe J
    [Continue or interrupt? Antirheumatic treatment in elective surgery].
    Z Rheumatol. 2022;81:492-500.
    PubMed     Abstract available
    
    
    
19. FIORI W, Lakomek HJ, Strunk J, Klemann A, et al
    [Rheumatologic inpatient treatment-more than a complex treatment : Data reflecting services and structures].
    Z Rheumatol. 2022;81:472-481.
    PubMed     Abstract available
    
    
    June 2022
20. MISCHKEWITZ M, Alten R
    [This is how we treat rheumatoid nodules in patients with rheumatoid arthritis in remission].
    Z Rheumatol. 2022 Jun 20. pii: 10.1007/s00393-022-01228.
    PubMed    
    
    
    
21. ALBRECHT K, Marschall U, Zink A, Callhoff J, et al
    [Prescription frequency of physical therapy for inflammatory rheumatic diseases].
    Z Rheumatol. 2022;81:360-368.
    PubMed     Abstract available
    
    
    May 2022
22. ZHANG G, Liu W, Zhang X, Liu L, et al
    Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation : Successful treatment by Tocilizumab.
    Z Rheumatol. 2022;81:335-338.
    PubMed     Abstract available
    
    
    April 2022
23. BEIL FT
    [What are the indications for a synovectomy?]
    Z Rheumatol. 2022;81:236-239.
    PubMed     Abstract available
    
    
    March 2022
24. ALBRECHT K, Callhoff J, Strangfeld A
    [Is the prevalence of rheumatoid arthritis truly on the rise?]
    Z Rheumatol. 2022 Mar 31. pii: 10.1007/s00393-022-01192.
    PubMed     Abstract available
    
    
    
25. MEISSNER Y, Strangfeld A
    [Latest findings from the RABBIT register].
    Z Rheumatol. 2022;81:100-109.
    PubMed     Abstract available
    
    
    
26. WITTE T
    [Janus kinase inhibitors].
    Z Rheumatol. 2022;81:94-99.
    PubMed     Abstract available
    
    
    
27. BRAUN J, Richter A, Schmidt C, Baraliakos X, et al
    [Answering epidemiologic rheumatologic questions by cooperation with the large population-based SHIP cohort-findings with relevance for the diagnosis of axial spondyloarthritis (axSpA)].
    Z Rheumatol. 2022;81:150-156.
    PubMed     Abstract available
    
    
    
28. SHENG Z, Zeng J, Huang W, Li L, et al
    Comparison of therapeutic efficacy and mechanism of paclitaxel alone or in combination with methotrexate in a collagen-induced arthritis rat model.
    Z Rheumatol. 2022;81:164-173.
    PubMed     Abstract available
    
    
    
29. ALBRECHT K, Kruger K
    [New aspects on treatment of RA].
    Z Rheumatol. 2022;81:91-93.
    PubMed    
    
    
    February 2022
30. LEE YH, Song GG
    Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Z Rheumatol. 2022 Feb 10. pii: 10.1007/s00393-022-01165.
    PubMed     Abstract available
    
    
    
31. REGEL A, Foll D, Kriegel MA
    [Still's syndrome-similarities and differences between the juvenile and adult forms].
    Z Rheumatol. 2022;81:22-27.
    PubMed     Abstract available
    
    
    January 2022
32. KRUGER K
    [Innovative strategies for treatment of rheumatoid arthritis].
    Z Rheumatol. 2022 Jan 7. pii: 10.1007/s00393-021-01144.
    PubMed     Abstract available
    
    
    December 2021
33. RUFFER N, Tomas NM, Schmiedel S, Jordan S, et al
    [Erratum to: Visceral leishmaniasis mimicking Felty's syndrome in rheumatoid arthritis treated with methotrexate and etanercept].
    Z Rheumatol. 2021 Dec 21. pii: 10.1007/s00393-021-01143.
    PubMed    
    
    
    
34. WITTE F, Lakomek HJ, Holzinger J, Reinbold WD, et al
    [Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis].
    Z Rheumatol. 2021 Dec 1. pii: 10.1007/s00393-021-01133.
    PubMed     Abstract available
    
    
    
35. KNAB K, Chambers D, Kronke G
    [Protective macrophages : New insights into the role of synovial macrophages in inflammatory joint diseases].
    Z Rheumatol. 2021;80:966-971.
    PubMed     Abstract available
    
    
    November 2021
36. MORF H, Witte T
    [Use of biosimilars in the treatment of rheumatoid arthritis : An overview].
    Z Rheumatol. 2021 Nov 26. pii: 10.1007/s00393-021-01129.
    PubMed     Abstract available
    
    
    
37. SUNG YK, Lee YH
    The lessebo effect in randomized controlled trials of rituximab in patients with rheumatoid arthritis: a meta-analysis.
    Z Rheumatol. 2021 Nov 10. pii: 10.1007/s00393-021-01126.
    PubMed     Abstract available
    
    
    
38. KLEINERT S
    [Data analysis in rheumatology practices : Possibilities, limitations, and results].
    Z Rheumatol. 2021;80:827-834.
    PubMed     Abstract available
    
    
    October 2021
39. HAAS JP, Weimann V, Feist E
    [Polyarticular juvenile idiopathic arthritis and rheumatoid arthritis : Common features and differences].
    Z Rheumatol. 2021 Oct 28. pii: 10.1007/s00393-021-01114.
    PubMed     Abstract available
    
    
    
40. KILTZ U, Buschhorn-Milberger V, Albrecht K, Lakomek HJ, et al
    [Development of quality standards for patients with rheumatoid arthritis for use in Germany].
    Z Rheumatol. 2021 Oct 15. pii: 10.1007/s00393-021-01093.
    PubMed     Abstract available
    
    
    
41. RUFFER N, Tomas NM, Schmiedel S, Jordan S, et al
    [Visceral leishmaniasis mimicking Felty's syndrome in rheumatoid arthritis treated with methotrexate and etanercept].
    Z Rheumatol. 2021 Oct 11. pii: 10.1007/s00393-021-01105.
    PubMed     Abstract available
    
    
    
42. LAKOMEK HJ, Rudwaleit M, Hentschel A, Broge B, et al
    [Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics].
    Z Rheumatol. 2021;80:758-770.
    PubMed     Abstract available
    
    
    September 2021
43. TEKAYA R, Rouached L, Ben Ahmed H, Ben Tekaya A, et al
    Variation of homocysteine levels in rheumatoid arthritis patients: relationship to inflammation, cardiovascular risk factors, and methotrexate.
    Z Rheumatol. 2021 Sep 27. pii: 10.1007/s00393-021-01092.
    PubMed     Abstract available
    
    
    
44. MAO YM, Liao T, Ye QL, Wu GC, et al
    Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis.
    Z Rheumatol. 2021 Sep 20. pii: 10.1007/s00393-021-01091.
    PubMed     Abstract available
    
    
    
45. PARDEY N, Zeidler J, Nellenschulte TF, Stahmeyer JT, et al
    [Methotrexate treatment before use of biologics in rheumatoid arthritis : Analysis of guideline compliance].
    Z Rheumatol. 2021 Sep 20. pii: 10.1007/s00393-021-01086.
    PubMed     Abstract available
    
    
    July 2021
46. SUNG YK, Lee YH
    Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-anal
    Z Rheumatol. 2021 Jul 9. pii: 10.1007/s00393-021-01047.
    PubMed     Abstract available
    
    
    
47. LEE YH, Song GG
    Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis.
    Z Rheumatol. 2021 Jul 6. pii: 10.1007/s00393-021-01040.
    PubMed     Abstract available
    
    
    
48. HO LEE Y, Gyu Song G
    Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Z Rheumatol. 2021 Jul 5. pii: 10.1007/s00393-021-01041.
    PubMed     Abstract available
    
    
    June 2021
49. CHRISTENN M
    [Immunogenicity and safety of high dose vs. standard dose of inactivated influenza vaccine in patients with rheumatoid arthritis].
    Z Rheumatol. 2021 Jun 25. pii: 10.1007/s00393-021-01030.
    PubMed    
    
    
    
50. VALOR-MENDEZ L, Manger B, Schett G, Kleyer A, et al
    [Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
    Z Rheumatol. 2021 Jun 7. pii: 10.1007/s00393-021-01020.
    PubMed     Abstract available
    
    
    
51. SIEROCINSKI E, Angelow A, Mainz A, Walker J, et al
    [Patient safety in the treatment of rheumatic diseases : Laboratory monitoring in methotrexate treatment].
    Z Rheumatol. 2021;80:418-424.
    PubMed     Abstract available
    
    
    May 2021
52. LEE YH, Song GG
    Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.
    Z Rheumatol. 2021 May 17. pii: 10.1007/s00393-021-01013.
    PubMed     Abstract available
    
    
    April 2021
53. ARTZT B, Arndt M, Wickler B, Rehart S, et al
    [Gigantic prepatellar "tumor" in rheumatoid arthritis-a case report].
    Z Rheumatol. 2021 Apr 30. pii: 10.1007/s00393-021-01010.
    PubMed     Abstract available
    
    
    
54. ALBRECHT K, Zink A
    [If smoking, then also drinking? : New aspects on the influence of alcohol and smoking on the risk for rheumatoid arthritis].
    Z Rheumatol. 2021 Apr 20. pii: 10.1007/s00393-021-01004.
    PubMed    
    
    
    
55. HARTUNG W, Sewerin P, Ostendorf B
    [Sports and exercise therapy in inflammatory rheumatic diseases].
    Z Rheumatol. 2021;80:251-262.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Rheumatoid Arthritis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: